This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Health Stock Winners and Losers: J&J Raises Dividend

Updated from 5:10 p.m. EDT

Health stocks were mixed Thursday on a smattering of news, including an announcement that Johnson & Johnson (JNJ - Get Report) had raised its dividend.

Johnson & Johnson said that because of its performance in 2008 and generally strong financial position, it is raising its quarterly dividend 6.5% to 49 cents from 46 cents. The next quarterly dividend will be payable June 9 to shareholders of record as of May 26.

Johnson & Johnson's shares rose 0.4% to close at $51.40.

Biotech Select

Meanwhile, Pfizer (PFE - Get Report) shareholders tentatively approved a "say on pay" proposal asking that they receive an advisory vote on executive compensation and a proposal to make it easier to call a special shareholder meeting, according to The Associated Press. Shares rose 1.8% to $13.28.

Merck (MRK) shares rose 1.1% to $23.23 after Cigna Corp. (CI) announced a deal in which its customers can receive increased discounts on Merck's oral antidiabetes medications Januvia and Janumet.

Cigna said it will review available A1C lab values for people taking any oral antidiabetic medications. If these values have improved by the end of the year, the discounts Merck offers on Januvia and Janumet will increase. Cigna also will review claims data for its pharmacy customers who take Januvia or Janumet. If these customers are taking the drugs as prescribed, Cigna said, Merck will increase the discounts it offers Cigna on these medications even more.

In other diabetes drug news, the FDA said it needs more time to review an application from Bristol-Myers Squibb (BMY - Get Report) and AstraZeneca (AZN) for their diabetes drug Onglyza. Bristol shares rose 1.8% to $20.17, and AstraZeneca shares rose 2% to $34.05.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
BMY $67.53 -1.10%
GSK $44.06 -2.70%
JNJ $101.13 -0.22%
LLY $74.23 -0.09%
NVS $102.30 -1.50%

Markets

DOW 18,045.28 -186.74 -1.02%
S&P 500 2,105.97 -20.09 -0.94%
NASDAQ 5,031.19 -58.1720 -1.14%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs